Bio-Thera Solutions
56
6
10
32
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
16.1%
9 terminated/withdrawn out of 56 trials
78.0%
-8.5% vs industry average
18%
10 trials in Phase 3/4
3%
1 of 32 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (56)
To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors
Role: lead
Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors
Role: lead
Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients
Role: lead
A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis
Role: lead
Clinical Study of Stage IV Psoriasis in Children With Geleli
Role: lead
Evaluate the Safety, Tolerability of BAT6026
Role: lead
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection
Role: lead
A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer
Role: lead
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection
Role: lead
A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants
Role: lead
A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors
Role: lead
Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid Tumors
Role: lead
A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
Role: lead
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration
Role: lead
Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China
Role: lead
BAT7104 Injection in Patients With Advanced Malignant Tumors.
Role: lead
A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC
Role: lead
BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer
Role: lead
A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors
Role: lead
Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour Patients
Role: lead